Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Pharmacology, Toxicology and Pharmaceutical Science
4
6%
Agricultural and Biological Sciences
4
6%
Other
5
7%
Unknown
32
44%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2023.
All research outputs
#10,395,242
of 34,089,221 outputs
Outputs from Clinical Cancer Research
#10,434
of 17,747 outputs
Outputs of similar age
#141,069
of 393,967 outputs
Outputs of similar age from Clinical Cancer Research
#153
of 242 outputs
Altmetric has tracked 34,089,221 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 17,747 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,967 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
